

Grand Valley State University Institutional Review Board (IRB)	
Title: <i>Informed Consent: General [Revised Common Rule Version]</i>	
Section: 810b.	This policy and procedure supersedes those previously drafted
Approved by HRRC: 02/14/2012 Revisions approved 04/08/2014; 10/28/2014 Revisions Approved by HRRPPC: 04/24/2018 Revisions Approved by HRRPPC: 09/25/2018 Revisions Approved by IRBPPC: 10/20/2023 Revisions Approved by IRBPPC: 02/03/2025	Approved by RIO/HRPA: 02/16/2012 Revisions approved 04/08/2014; 10/28/2014 Approved by AIO/RIO: 05/09/2018 Approved by AIO/RIO: 12/19/2018 Approved by AIO/RIO: 3/16/2020 Approved by AIO/RIO: 11/06/2023 Approved by IO: 06/15/2025
Effective Date: 06/15/2025	
Related documents: <i>120: Compliance with Applicable Laws and Regulations</i> <i>710: Assessing Risk to Research Participants</i> <i>720: Assessing Risk to Vulnerable Participants</i> <i>730: Collection, Management and Security of Research Information</i> <i>760: Research Utilizing HIPAA-Protected Health Information</i> <i>812: Research Involving Children</i> <i>813: Research Involving Participants with Questionable Consent Capacity and/or Legally Authorized Representatives</i> <i>814: Informed Consent for Persons Not Fluent in the Primary Language of the Study</i> <i>820: Waivers, Alterations, and Exceptions to Informed Consent Process and Documentation</i> <i>G-7: Guidance on Obtaining Informed Consent</i> <i>G-20: ClinicalTrials.gov Registration Guidance</i>	

Policy

1. Federal regulations and IRB policy require that, for all non-exempt research, the researcher must *obtain and document* legally and ethically valid informed consent from the subject or the subject's legally authorized representative *prior to* enrolling the subject in the research, unless the IRB has approved a waiver.
 - a. For exempt research involving interactions or interventions with subjects, the researcher must *obtain* legally and ethically valid informed consent from the subject or the subject's legally authorized representative *prior to* enrolling the subject in the research. (Note the informed consent process used for exempt research does not necessarily require the researcher to obtain *written* consent from the subject or subject's legally authorized representative; however, a consent process must be documented in the protocol.)
 - b. The prospective subject or the subject's legally authorized representative must be provided with the information that a reasonable person would want to have in order to make an informed decision about whether to participate, and an opportunity to discuss that information.
 - c. Consent from research participants or their legal representative must be free from coercion and undue influence, obtained in accordance with applicable laws, and acquired through culturally appropriate means.

2. For research subject to HIPAA and/or FDA oversight, the participant must receive a copy of the signed consent documentation, unless the IRB has approved a waiver of consent or an alteration of consent indicating written consent information does not need to be provided to the participants.
3. Special consent, assent, and permission requirements may apply to identified vulnerable participants. Some conditions exist that may allow for waivers, alterations or exceptions to the standard informed consent requirements as allowed under the regulations.
4. Clinical Trials
 - a. For applicable FDA-regulated clinical trials, under 21 CFR 50.25(c), the following statement must be reproduced word-for-word in informed consent documents:

“A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”
 - b. For clinical trials supported by Federal funding and/or subject to federal regulatory oversight, the following requirements exist for the posting of clinical trial forms, per 45 CFR 46.116(h):
 - i. For each clinical trial conducted or supported by a Federal department or agency, one IRB-approved informed consent form used to enroll subjects must be posted by the awardee or the Federal department or agency component conducting the trial on a publicly available Federal website that will be established as a repository for such informed consent forms.
 - ii. If the Federal department or agency supporting or conducting the clinical trial determines that certain information should not be made publicly available on a Federal website (e.g. confidential commercial information), such Federal department or agency may permit or require redactions to the information posted.
 - iii. The informed consent form must be posted on the Federal website after the clinical trial is closed to recruitment, and no later than 60 days after the last study visit by any subject, as required by the protocol.

Procedures

1. Non-Exempt Research: Elements of Ethically and Legally Valid Informed Consent
 - a. Informed consent as a whole must present information in sufficient detail relating to the research and must be organized and presented in a way that does not merely provide lists of isolated facts, but rather facilitates the prospective subject's or the subject's legally authorized representative's understanding of the reasons why one might or might not want to participate.
 - b. Informed consent documents may not contain any exculpatory language; that is, language which states, suggests or implies that the participant waives any legal rights or to release the researcher, the sponsor, or the University from liability for negligence.

- c. Informed consent shall include written and/or verbal expression of the following information components to minimize confusion or misunderstanding about the research.
- i. Name of the principal investigator.
 - ii. Name of the external sponsor or funding source, if applicable.
 - iii. A concise and focused presentation of the key information that is most likely to assist a prospective subject or legally authorized representative in understanding the reasons why one might or might not want to participate in the research. This section of the informed consent is required and must be organized and presented in a way that facilitates comprehension.
 - iv. A statement that the study involves research and an explanation of the purposes of the research.
 - v. A description of the expected duration of the total research participation, the procedures to be followed, including notice of any procedures that are experimental, and the approximate time required for each component.
 - vi. A description of any reasonably foreseeable risks or discomforts to the participant.
 - vii. A description of any reasonably anticipated benefits to the participant or to society.
 - viii. A description of alternatives to the research including not participating.
 - ix. A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained. This section must indicate that GVSU, the sponsor, and the FDA when applicable, will have access to identifiable records for purposes of study monitoring and research oversight.
 - x. Whom to contact in the event of research-related harm to the participant.
 - xi. Whom to contact with questions about the research.
 - xii. Whom to contact with questions about participants' rights, or concerns or complaints about the research or research team members.
 - xiii. A statement that participation is voluntary and refusing to participate or discontinuing participation will not lead to any penalty or loss of benefits to which the participant is otherwise entitled
 - xiv. A statement of what will be done with collected data if a participant withdraws from the research
 - xv. A signature line for the statement of agreement to participate as a research subject including the participant's printed name and date
 - xvi. For research involving more than minimal risk, an explanation as to whether any compensation and medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained.
 - xvii. One of the following statements about any research that involves the collection of identifiable private information or identifiable biospecimens:
 1. A statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after such removal, the information or biospecimens could be used for future research studies or distributed to another investigator for future research studies without additional informed consent from the subject or the legally authorized representative, if this might be a possibility.
 2. A statement that the subject's information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.
 - xviii. A statement indicating the protocol has been approved by the IRB at Grand Valley State University and the corresponding protocol number of the study.

- d. Informed consent shall include written and/or verbal expression of the following additional information *as needed* to minimize confusion or misunderstanding about the research. *Not every component is required for every study.*
- i. A description of any compensation for participation or that no compensation will be provided.
 - ii. A description of how participants will be selected and the basis for any inclusions or exclusions.
 - iii. A description of the circumstances when participation may be terminated by the researcher without the participant's consent.
 - iv. A description of the consequences of a subject's voluntary withdrawal from the research, if any, and procedures for orderly termination of participation.
 - v. Disclosure of any additional costs to the subject that may result from participation in the research.
 - vi. A statement that the particular treatment or procedure may involve risks to the subject (or embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.
 - vii. A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.
 - viii. A description of the approximate number of participants involved in the study.
 - ix. A statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit.
 - x. A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions.
 - xi. For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing.
 - xii. If the research is funded by the National Institutes of Health or the researcher will apply for a federal Certificate of Confidentiality, a description of the protections and limitations of the Certificate of Confidentiality, including the circumstances in which the investigator may voluntarily disclose identifying information about research participants (e.g., child abuse, harm to self or others, etc.).

2. Exempt Research: Elements of Ethically and Legally Valid Informed Consent

- a. Exempt research involving interactions with research subjects requires a consent process, either verbally or in writing, that shall include the following disclosures.
- i. Name of the principal investigator.
 - ii. A statement that the study involves research and an explanation of the purposes of the research.
 - iii. A description of the expected duration of the total research participation and the procedures to be followed.
 - iv. A statement that participation is voluntary and refusing to participate or discontinuing participation will not lead to any penalty or loss of benefits to which the participant is otherwise entitled.
 - v. A description of any reasonably foreseeable risks or discomforts to the participant, if any.
 - vi. A description of any reasonably anticipated benefits to the participant or to society, if any.

- vii. Whom to contact with questions about the research.
 - viii. Whom to contact with questions about participants' rights, or concerns or complaints about the research or research team members. A statement indicating the protocol has been reviewed by the IRB at Grand Valley State University and the corresponding protocol number of the study.
 - b. A written or electronic signature documenting consent is not required for exempt research, unless additional regulations or policies requiring signature apply to the research (i.e. Family Educational Rights and Privacy Act [FERPA], Health Insurance Portability and Accountability Act [HIPAA], General Data Protection Regulation [GDPR]).
 - c. An active (“opt-in”) consent process must be used for any study involving the collection of GDPR-covered data. See IRB Policy 120: *Compliance with Applicable Laws and Regulations* for more information.
3. Long-form and Short-form Consent for Non-Exempt Research
- a. If a written consent document is used it should include the GVSU logo and be written at a reading level that is appropriate for all potential participants (generally 6th-8th grade reading level). Use of the long form for documenting a legally and ethically valid consent process is the default requirement for all non-exempt research. The content of the long-form is specified above .
 - b. Unless a waiver or alteration is approved by the IRB, researchers must acquire informed consent and document it using either a long-form or a short form process. Note that the short form process requires, in addition to producing a summary of the long form, also producing and reading the content of the long form and providing a copy of it and of the short form to the research participant or their legally authorized representative.
 - c. The IRB does not require a witness to the consent when the long-form is used, though study sponsors may have different requirements. Per DHHS and FDA regulations, the long-form consent document must be signed (including in an electronic format and for FDA-regulated studies, the electronic format must be compliant with 21 CFR 11) and dated by the participant or the participant’s legally authorized representative. The original document must be kept in a secure location as described in IRB Policy 730: *Collection, Management and Security of Research Information* and must be retained as described in section d below. A copy of the consent document must be given to the participant or his/her legally authorized representative to keep.
 - d. The short-form consent is a brief document stating that the elements of informed consent as required for the long-form have been presented orally to the participant or the participant's legally authorized representative. The short-form consent is a method that is utilized with participants who are illiterate or otherwise unable to read and/or sufficiently understand the written long-form consent document.
 - i. The IRB must prospectively approve the use of the short-form consent process. The researcher shall describe in what populations it will be used and why the long-form consent process does not sufficiently meet the needs of the potential participants.

4. Retaining Consent Documents

- a. Documentation of participants' informed consent (either the signed [including in an electronic format] short-form and/or the long-form, or video or audio recordings of consent) are research-related records that must be retained for at least three (3) years after completion of the study, unless the IRB waived the requirement for informed consent and/or the documentation of informed consent. For FDA regulated studies the record retention is a minimum of five (5) years.
- b. Study record retention is the responsibility of the investigator. Consent records may be preserved in hardcopy or electronically copied and retained and the paper copies destroyed. Consent records must be accessible for inspection by the IRB or other authority. Retention of multiple copies of each record is not required.
- c. If a researcher designated to retain records on behalf of GVSU leaves the institution, the researcher and the Authorizing Official should identify a successor, when applicable, who shall take over responsibility for securely maintaining the research records, either at GVSU or at another location. See *IRB Policy 730: Collection, management and security of research information*.

5. Screening, Recruiting, or Determining Eligibility

Per 45 CFR 46.116(g), an IRB may approve a research proposal in which an investigator will obtain information or biospecimens for the purpose of screening, recruiting, or determining the eligibility of prospective subjects without the informed consent of the prospective subject or the subject's legally authorized representative, if either of the following conditions are met:

- a. The investigator will obtain information through oral or written communication with the prospective subject or legally authorized representative, or
- b. The investigator will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens.

6. International Conference on Harmonization – Good Clinical Practice (ICH-GCP)

- a. The GCP standards contained in the ICH document are not regulatory requirements in the United States, and the GVSU IRB does not review the consent documents for these additional elements. However, for externally-sponsored studies with contractual responsibility to adhere to ICH-GCP, the IRB will review the consent documents for these additional requirements.
- b. The principal investigator must indicate in the IRB protocol application that adherence to ICH-GCP is required, and the Office of Research Compliance and Integrity will verify this with the Office of Sponsored Programs.

Background

Legally and ethically valid informed consent to participate in research requires a process of ongoing dialogue between the researcher and each research participant. This dialogue should result in a shared understanding about what the research involves, what the participant will be asked to do, what risks and benefits the research procedures may entail, if any, and how the results of the research are expected to be used. Informed consent is not a participant's signature on a document or his or her agreement to

participate in research. It is a mutual understanding that includes an opportunity for the participant to ask questions and to receive full explanations prior to participating, throughout the research activity, and after it has been completed.